Literature DB >> 24766622

Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles.

Oliver Seifert1, Nadine Pollak, Anja Nusser, Frank Steiniger, Ronny Rüger, Klaus Pfizenmaier, Roland E Kontermann.   

Abstract

The TNF-related apoptosis-inducing ligand (TRAIL) is a powerful inducer of apoptosis in tumor cells; however, clinical studies with recombinant soluble TRAIL were rather disappointing. Here, we developed TRAIL-functionalized liposomes (LipoTRAIL, LT) to mimic membrane-displayed TRAIL for efficient activation of death receptors DR4 and DR5 and enhanced induction of apoptosis, which were combined with an anti-EGFR single-chain Fv fragment (scFv) for targeted delivery to EGFR-positive tumor cells. These immuno-LipoTRAILs (ILTs) bound specifically to EGFR-expressing cells (Colo205) and exhibited increased cytotoxicity compared with that of nontargeted LTs. Compared to that of the soluble TRAIL, the plasma half-life of the functionalized liposomes was strongly extended, and increased antitumor activity of LT and ILT was demonstrated in a xenograft tumor model. Thus, we established a multifunctional liposomal TRAIL formulation (ILT) with improved pharmacokinetic and pharmacodynamic behavior, characterized by targeted delivery and increased induction of apoptosis due to multivalent TRAIL presentation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24766622     DOI: 10.1021/bc400517j

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  12 in total

1.  Advances in Anticancer Protein Delivery Using Micro-/ Nanoparticles.

Authors:  Wujin Sun; Yue Lu; Zhen Gu
Journal:  Part Part Syst Charact       Date:  2014-10-16       Impact factor: 3.310

2.  Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells.

Authors:  D De Miguel; A Gallego-Lleyda; P Galan-Malo; C Rodriguez-Vigil; I Marzo; A Anel; L Martinez-Lostao
Journal:  Clin Transl Oncol       Date:  2015-05-13       Impact factor: 3.405

3.  Self-assembled peptide nanostructures targeting death receptor 5 and encapsulating paclitaxel as a multifunctional cancer therapy.

Authors:  Tyson J Moyer; Feng Chen; Daniel J Toft; Yves Ruff; Vincent L Cryns; Samuel I Stupp
Journal:  ACS Biomater Sci Eng       Date:  2019-10-23

Review 4.  Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.

Authors:  Pedro P G Guimarães; Stephanie Gaglione; Tomasz Sewastianik; Ruben D Carrasco; Robert Langer; Michael J Mitchell
Journal:  ACS Nano       Date:  2018-02-06       Impact factor: 15.881

5.  TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer.

Authors:  Elizabeth C Wayne; Siddarth Chandrasekaran; Michael J Mitchell; Maxine F Chan; Rachel E Lee; Chris B Schaffer; Michael R King
Journal:  J Control Release       Date:  2015-12-28       Impact factor: 9.776

Review 6.  Onto better TRAILs for cancer treatment.

Authors:  D de Miguel; J Lemke; A Anel; H Walczak; L Martinez-Lostao
Journal:  Cell Death Differ       Date:  2016-03-04       Impact factor: 15.828

Review 7.  Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).

Authors:  Mohammed I Y Elmallah; Olivier Micheau
Journal:  Mar Drugs       Date:  2015-11-13       Impact factor: 5.118

8.  Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.

Authors:  Mesha Saeed; Mandy van Brakel; Sara Zalba; Erik Schooten; Joost A P Rens; Gerben A Koning; Reno Debets; Timo L M Ten Hagen
Journal:  Int J Nanomedicine       Date:  2016-03-08

9.  Pro-apoptotic effect of TRAIL-transfected endothelial progenitor cells on glioma cells.

Authors:  Xin Deng; Wen Zhao; Laijun Song; Wei Ying; Xinbin Guo
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

10.  TRAIL-functionalized gold nanoparticles selectively trigger apoptosis in polarized macrophages.

Authors:  Yen-Jang Huang; Shan-Hui Hsu
Journal:  Nanotheranostics       Date:  2017-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.